CN1897965A - 反应性的化学剂、生物剂或毒素引起的生物反应或免疫反应的治疗方法或预防方法 - Google Patents

反应性的化学剂、生物剂或毒素引起的生物反应或免疫反应的治疗方法或预防方法 Download PDF

Info

Publication number
CN1897965A
CN1897965A CNA200480038178XA CN200480038178A CN1897965A CN 1897965 A CN1897965 A CN 1897965A CN A200480038178X A CNA200480038178X A CN A200480038178XA CN 200480038178 A CN200480038178 A CN 200480038178A CN 1897965 A CN1897965 A CN 1897965A
Authority
CN
China
Prior art keywords
tissue
response
biological
immune response
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA200480038178XA
Other languages
English (en)
Chinese (zh)
Inventor
阿兰·L.·戈尔茨坦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RegeneRx Biopharmaceuticals Inc
Original Assignee
RegeneRx Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by RegeneRx Biopharmaceuticals Inc filed Critical RegeneRx Biopharmaceuticals Inc
Publication of CN1897965A publication Critical patent/CN1897965A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57581—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CNA200480038178XA 2003-12-22 2004-12-22 反应性的化学剂、生物剂或毒素引起的生物反应或免疫反应的治疗方法或预防方法 Pending CN1897965A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53089303P 2003-12-22 2003-12-22
US60/530,893 2003-12-22

Publications (1)

Publication Number Publication Date
CN1897965A true CN1897965A (zh) 2007-01-17

Family

ID=34738610

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA200480038178XA Pending CN1897965A (zh) 2003-12-22 2004-12-22 反应性的化学剂、生物剂或毒素引起的生物反应或免疫反应的治疗方法或预防方法

Country Status (7)

Country Link
US (1) US20090053194A1 (https=)
EP (1) EP1706136A4 (https=)
JP (1) JP2007521336A (https=)
CN (1) CN1897965A (https=)
AU (1) AU2004308378B2 (https=)
CA (1) CA2550833A1 (https=)
WO (1) WO2005062864A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1755661B1 (en) * 2004-05-12 2014-03-12 The Brigham And Women's Hospital, Inc. Gelsolin for use in treating infections
ES2641879T3 (es) 2006-03-15 2017-11-14 The Brigham And Women's Hospital, Inc. Uso de gelsolina para diagnosticar y tratar enfermedades inflamatorias
US8580738B2 (en) 2007-04-30 2013-11-12 The Board Of Regents Of The University Of Texas System Methods for treatment of reperfusion injury and other cardiac conditions
RU2364396C2 (ru) * 2007-11-07 2009-08-20 ФГУН "Нижегородский научно-исследовательский институт гигиены и профессиональной патологии" Роспотребнадзора Способ профилактики и коррекции иммунных нарушений, вызываемых токсическими веществами
DK2250280T3 (en) 2008-01-25 2015-03-09 Gen Hospital Corp THERAPEUTIC USES OF gelsolin in renal failure
CN101297965B (zh) * 2008-06-16 2011-01-05 浙江省中医药研究院 胸腺肽β4在制备防治支气管哮喘药物中的应用
WO2012126047A1 (en) * 2011-03-18 2012-09-27 Adistem Ltd Agent and method for treating pain and reducing inflammation
US20230025377A1 (en) * 2020-02-13 2023-01-26 HLB Therapeutics Co., Ltd. Compositions and methods for treating or preventing pruritus

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9806632D0 (en) * 1998-03-28 1998-05-27 Stevenson Robert Peptide factor
AU766826B2 (en) * 1998-07-30 2003-10-23 Government of The United States of America, as represented by The Secretary Department of Health & Human Services, The National Institutes of Health, The Thymosin beta4 promotes wound repair
EP1296704A4 (en) * 2000-06-14 2005-04-27 Chanda Bhuwalka Zaveri PEPTIDES WITH PHYSIOLOGICAL ACTIVITY
CA2446072A1 (en) * 2001-05-17 2002-11-21 Regenerx Biopharmaceuticals, Inc. Treating epidermolysis bullosa with thymosin beta 4
WO2003020215A2 (en) * 2001-08-29 2003-03-13 Regenerx Biopharmaceuticals, Inc. Methods of treating mycocardial event related coditions with thymosin beta 4
AU2003223601A1 (en) * 2002-04-12 2003-10-27 King's College London ANTI-INFLAMMATORY AND WOUND HEALING EFFECTS OF LYMPHOID THYMOSIN Beta 4

Also Published As

Publication number Publication date
AU2004308378A1 (en) 2005-07-14
AU2004308378B2 (en) 2010-05-13
EP1706136A4 (en) 2009-09-16
WO2005062864A2 (en) 2005-07-14
EP1706136A2 (en) 2006-10-04
CA2550833A1 (en) 2005-07-14
WO2005062864A3 (en) 2006-06-29
JP2007521336A (ja) 2007-08-02
US20090053194A1 (en) 2009-02-26

Similar Documents

Publication Publication Date Title
US20060089310A1 (en) Treatment of infections and other disorders
JP2009179638A (ja) サイモシンβ４（Ｔβ４）、類似体、アイソホーム、および他の誘導体を含む組成物の使用
JP2005502672A (ja) サイモシンβ４、類似体、アイソフォームおよびその他の誘導体を用いて心筋障害の発生前、発生中または発生後に発生する炎症、損傷およびその他の変化を治癒または予防する方法
CN1897965A (zh) 反应性的化学剂、生物剂或毒素引起的生物反应或免疫反应的治疗方法或预防方法
AU2002255736A1 (en) Methods of Treating Disorders of the Eye and Surrounding Tissue with Thymosin Beta4 (TBeta4), Analogues, Isoforms and Other Derivatives
JP2009046502A (ja) 皮膚状態の改善を促進するための組成物の製造のための、アミノ酸配列ｌｋｋｔｅｔを含む皮膚変性阻害ポリペプチドの使用
US8716215B2 (en) Method of treating or preventing tissue deterioration, injury or damage due to a neuro-, muscular- or neuro-muscular-degenerative disease, or restore tissue adversely affected by said disease
US20110020449A1 (en) Methods of treating disorders of the eye and surrounding tissue with thymosin beta 4 (tb4), analogues, isoforms and other derivatives
JP2007521336A5 (https=)
US20060246057A1 (en) Treatment or prevention of damage due to radiation exposure
US20080051348A1 (en) Treatment of infections and other disorders
MXPA06006849A (en) Method of treating or preventing biological or immunological responses to a reactive chemical or biological or toxic agent
KR20070019668A (ko) 반응성 화학물질 또는 생물학적 물질 또는 독성 물질에대한 생물학적 또는 면역학적 반응들의 치료 또는 예방방법
WO2006076255A2 (en) Method of treating or preventing microbial eye infection
WO2006076254A2 (en) Method of treating or preventing respiratory microbial infection of respiratory tissue

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20070117